Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

University of Virginia School of Medicine scientists have uncovered a key reason why HIV remains so difficult to cure: Their research shows that small changes in the virus affect how quickly or slowly ...

40 million people live with HIV globally, and that number continues to rise. While therapies exist to reduce the amount of HIV in a patient's body and, in turn, reduce HIV symptoms, there remains no ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

University of Virginia School of Medicine scientists have uncovered a key reason why HIV remains so difficult to cure, bringing researchers closer to finding ways to flush out the dormant virus and ...

In individuals who started antiretroviral therapy during acute HIV infection, the proliferative capacity of HIV-specific CD8+ ...